Methodological reporting of randomized controlled trials in major hepato-gastroenterology journals in 2008 and 1998: a comparative study

Ji-Lin Wang†, Tian-Tian Sun†, Yan-Wei Lin, Rong Lu and Jing-Yuan Fang*

Abstract

Background: It was still unclear whether the methodological reporting quality of randomized controlled trials (RCTs) in major hepato-gastroenterology journals improved after the Consolidated Standards of Reporting Trials (CONSORT) Statement was revised in 2001.

Methods: RCTs in five major hepato-gastroenterology journals published in 1998 or 2008 were retrieved from MEDLINE using a high sensitivity search method and their reporting quality of methodological details were evaluated based on the CONSORT Statement and Cochrane Handbook for Systematic Reviews of Interventions. Changes of the methodological reporting quality between 2008 and 1998 were calculated by risk ratios with 95% confidence intervals.

Results: A total of 107 RCTs published in 2008 and 99 RCTs published in 1998 were found. Compared to those in 1998, the proportion of RCTs that reported sequence generation (RR, 5.70; 95%CI 3.11-10.42), allocation concealment (RR, 4.08; 95%CI 2.25-7.39), sample size calculation (RR, 3.83; 95%CI 2.10-6.98), incomplete outcome data addressed (RR, 1.81; 95%CI, 1.03-3.17), intention-to-treat analyses (RR, 3.04; 95%CI 1.72-5.39) increased in 2008. Blinding and intention-to-treat analysis were reported better in multi-center trials than in single-center trials. The reporting of allocation concealment and blinding were better in industry-sponsored trials than in public-funded trials. Compared with historical studies, the methodological reporting quality improved with time.

Conclusion: Although the reporting of several important methodological aspects improved in 2008 compared with those published in 1998, which may indicate the researchers had increased awareness of and compliance with the revised CONSORT statement, some items were still reported badly. There is much room for future improvement.

Background

In the field of evidence-based medicine, randomized controlled trials (RCTs) with a logical design and correct implementation are considered to provide the best evidence for healthcare interventions [1]. In order to assess RCTs accurately, readers need complete, clear, and transparent information with regards to the design and conduction of the trials. Inappropriate experimental design and/or reporting usually lead to confusion in data interpretation. For example, unclear or inadequate allocation concealment is associated with an overestimation of treatment effect [2-4]. Therefore, adequate reporting of clinical trials, especially the methodological characteristics, is crucial for readers to appraise their validity.

In order to improve the quality of reporting in RCTs, the Consolidated Standards of Reporting Trials (CONSORT) statement was developed. Since it was published in 1996, it has been gradually accepted by many medical journals and has been associated with improvement of the quality of RCT reporting [5-8]. The statement was subsequently revised in 2001 and updated in 2010. We conducted this study in an attempt to evaluate the reporting qualities of key methodological items in RCTs from five major hepato-gastroenterology journals in
1998, 3 years before the revised version of CONSORT, and in 2008, 7 years after its revised version. We assessed whether the methodological reporting quality has improved over this 10 year period, especially before and after the publication of the revised version of the CONSORT in 2001.

Methods

Information source

We used a highly sensitive search strategy based on the Cochrane Handbook for Systematic Reviews of Interventions (Version 5.0.2) [9] to retrieve relevant RCTs published in the five highest impact factor journals of gastroenterology and hepatology (American Journal of Gastroenterology, Gastroenterology, Gut, Hepatology, and the Journal of Hepatology) in 1998 or 2008 from MEDLINE. In order to identify missing RCTs, these five journals were also manually searched.

Inclusion criteria

Only RCTs were eligible in our analysis. The trial was defined as a RCT if “random” was mentioned when participants were assigned to interventions. The following trial reports were excluded: reports published in a summary form or as reviews of randomized trials, reports on randomized trials on animals or healthy volunteers, and reports that did not describe the intervention outcome of randomly allocated patients.

Data extraction

Two authors (JW & TS), who were blinded to each other's results, screened all titles and abstracts of possibly relevant RCTs, and then selected RCTs in accordance with the predetermined eligibility criteria; studies were discarded that were not applicable by reviewing the full texts. One author (JW) extracted data from all articles, while another (TS) randomly selected 50 RCTs (24% of the sample) and extracted data independently using the same methods. Differences generated in data extraction were resolved by discussion and the senior reviewer (JF) was asked for help when disagreement could not be resolved by discussion.

Standards of methodological reporting

Based on the Cochrane Handbook for Systematic Reviews of Interventions and the CONSORT statement [10], seven items that were deemed important to avoid bias of the effect estimation were extracted for assessment. The seven methodological items were as follows: (1) random allocation sequence generation, classified as adequate reporting (when methods used to generate random sequence, randomization type, and restriction details were all reported), partial reporting (only parts of details were reported), and no reporting; (2) allocation concealment, classified as adequate reporting (when mechanism used to implement random sequence, and whether concealed sequence until interventions assigned were both reported), partial reporting (only parts of details were reported), and no reporting; (3) blinding, classified as adequate reporting (people who were blinded after assignment to interventions and how blinding was conducted, description of the similarity of interventions were all reported), partial reporting (only parts of details were reported), and no reporting; (4) sample size calculation, classified as adequate reporting (description of the methods of determining sample size and explanation of any interim analyses and stopping guidelines), partial reporting (only parts of details were reported), and no reporting; (5) incomplete outcome data addressed, classified as adequate reporting (missing outcome data was shown and whether the missing outcome data had a clinically relevant impact on intervention effect estimate), partial reporting (only parts of details were reported), and no reporting; (6) intention to treat analysis, classified as adequate reporting (how many participants were included in each analysis and whether the analysis was by original assigned groups), partial reporting (only parts of details were reported), and no reporting; (7) free of selective reporting, classified as adequate reporting (reporting all planned primary and secondary end points), partial reporting (only parts of details were reported), and no reporting.

Data analysis

Cohen’s kappa analysis [11] was performed to measure the level of agreement between the reviewers on all items of the data abstraction form. Agreement was judged as poor (kappa < 0.2), fair (0.21< kappa < 0.4), moderate (0.41< kappa < 0.6), substantial (0.61< kappa < 0.8), or good (kappa > 0.8).

We reported categorical data as frequencies, percentages, and 95% confidence interval (95%CI), using the Wilson Scoring method. Differences of the reporting quality of key methodological items in proportions in 1998 versus 2008 were tested using Chi-square analysis, and expressed as risk ratio (RR) with 95%CI. P-values were two-tailed and those < 0.05 were considered statistically significant. All of the statistical analysis was conducted using SAS 9.2 software (SAS Institute Inc. USA).

Results

Search results

Flow diagram of the search strategy and review process was detailed in Figure 1. Finally, a total of 206 RCTs (107 in 2008 and 99 published in 1998) were included. Kappa scores of data extracted independently by the two authors (JW and TS) were all greater than 0.80, indicating good agreement.
Characteristics of included trials

RCTs published in 2008 with a median of 167 participants and a median of 356 days follow-up period covered 26 diseases, while RCTs in 1998, with a median of 94 participants and a median of 178 days follow-up period, covered 24 diseases. In 1998, single-center trials were more common than multi-center trials, but in 2008 more than 70% of trials were conducted in multiple centers. Funding source information is important for readers to assess therapeutic effects. The number funded by industry increased in 2008. Characteristics of the included trials were detailed in Table 1.

Reporting of methodological items

Referring only to the items reported adequately, there was an increase in the proportion of trial reports that included adequate details of sequence generation (RR, 2.44; 95%CI 1.09-5.42; 10% in 1998 vs. 22% in 2008), sample size calculation (RR, 2.34; 95%CI 1.14-4.84; 13% in 1998 vs. 28% in 2008), intention-to-treat analysis (RR, 1.94; 95% CI 1.1-3.45; 30% in 1998 vs. 46% in 2008) between 1998 and 2008. Considering items reported adequately or partly as they had been reported, RCTs in 2008 had better reporting of the methodological items of sequence generation (RR, 5.70; 95%CI 3.11-10.42; 35% in 1998 vs. 76% in 2008), allocation concealment (RR, 4.08; 95%CI 2.25-7.39; 25% in 1998 vs. 62% in 2008), sample size calculation (RR, 3.83; 95%CI 2.10-6.98; 47% in 1998 vs. 78% in 2008), intention-to-treat analyses (RR, 3.04; 95%CI 1.72-5.39; 42% in 1998 vs. 69% in 2008), incomplete outcome data addressed (RR, 1.81; 95%CI 1.03-3.17; 34% in 1998 vs. 49% in 2008) than those published in 1998. However, no clear difference emerged in the reporting of blinding (RR, 1.25; 95%CI 0.72-2.16), free of selective reporting (RR, 1.48; 95%CI 0.86-2.57), and free of other bias (RR, 0.90; 95% CI 0.50-1.61) between the two selected years (Table 2).

Methodological reporting quality in 2008 according to different strata

We explored the association between the methodological reporting quality and center and funding source. In this section, we also took the items reported adequately or partly as they had been reported. The results showed that the methods of blinding and intention-to-treat analysis are related to the number of centers involved. Multi-center trials had better reporting of these two methodological items than single-center trials. As for the effects of different funding, allocation concealment and blinding were observed to be reported better in industry-sponsored trials than in public-funded trials. The reporting of other items were not associated with center or funding source (Table 3).

Discussion

Accurate description of methodology is essential for readers to assess the internal and external validity of RCTs. In this study, reporting quality of key methodological items of RCTs published in five major gastroenterology and hepatology journals in 2008 or 1998 were systematically assessed and compared. We identified an improvement in the key items of sequence generation, allocation concealment, sample size calculation, intention-to-treat analyses, and addressing of incomplete outcome data in 2008 compared with 1998. Nevertheless, the methodological reporting quality was still unsatisfactory.

Although the method of sequence generation was reported in more than twice as many articles published in 2008 than in 1999, 24% of articles still had inadequate information about this item. According to the latest CONSORT statement [10], adequate description of random allocation sequence generation should contain at least three aspects: methods used to generate the random sequence, randomization type, and restriction details. Applying these criteria to assessment of these articles, the results were even more unsatisfactory. In 2008, 12 years after the CONSORT statement was first published, only 23 articles adequately described how the random allocation sequence was generated. Sequence concealment allocation is also crucial to avoid bias, but this item was not reported well either. In 1998, only a quarter of articles reported that generated allocation schedules were implemented by allocation concealment. Ten years later, only half of trials reported adopting allocation concealment. Without adequate information, readers cannot define the exact method used. At the same time, without adequate information readers were unclear whether the randomization process was free
from human alteration and whether the findings were valid because trials with poor or unexplained concealment were more likely to yield larger estimates of treatment effect [12]. Therefore, not only details of the mechanism used to implement the random allocation sequence are required, but also the steps taken to conceal the sequence, and who generated the random allocation sequence, enrolled and assigned participants are required.

In 1998, blinding was the best reported item among the seven key methodological items, but no significant improvement was observed in the next 10 years. This finding was in agreement with Amy’s conclusion that CONSORT adoption had little effect on blinding of participants [13]. According to the CONSORT statement, people who were blinded after assignment to interventions and how the blinding was conducted should be all reported. However, many articles only described trials as “double blinded” or “blinded”, without providing any details. In trials without reporting of blinding details, bias may occur either intentionally or unintentionally, so their results are not fully reliable. For patient-reported outcomes in particular, result surveyors should make every effort to eliminate measurement bias. A meta-epidemiological study found that effect estimates were exaggerated when blinding had not taken place in trials with subjective outcomes effect estimate [14].

An adequate number of participants is essential for the detection of clinically significant differences with a high power. From the results of previous studies [15-18] and our article, the reporting quality of this item is gradually improving. The internal validity of RCTs is also associated with study participation and continuation. Omitting participants withdrawing from the trials easily reintroduced imbalance and prevented readers from calculating the attrition rates for different experimental conditions, which led to an overestimate of treatment effectiveness [19]. However, this methodological item was seldom assessed in previous articles evaluating the methodological reporting of RCTs about digestive disease. To our knowledge, our study and Kjaergard’s study [16] are the only two studies evaluating the reporting condition of this item. Kjaergard only examined RCTs published in Hepatology and found that drop-outs and

### Table 1 Characteristics of included RCTs

| Administrative indicators | Trials in 2008 | Trials in 1998 | RR [95%CI] | p value |
|---------------------------|---------------|---------------|------------|---------|
| Top five kinds of disease |               |               |            |         |
| chronic hepatitis C       | 19(18%)       | 15(15%)       | 1.21 [0.58, 2.53] | P = 0.62 |
| inflammatory bowel disease| 17(16%)       | 11(11%)       | 1.51 [0.67, 3.41] | P = 0.32 |
| liver cirrhosis           | 11(10%)       | 12(12%)       | -          | -       |
| chronic hepatitis B       | 12(11%)       | -             | -          | -       |
| colorectal cancer         | 8(7%)         | -             | -          | -       |
| peptic ulcer              | -             | 15(15%)       | -          | -       |
| liver cancer              | -             | 5(5%)         | -          | -       |
| Region                    |               |               |            |         |
| North America             | 36(34%)       | 30(30%)       | 1.17 [0.65, 2.10] | P = 0.61 |
| Europe                    | 42(39%)       | 56(57%)       | 0.50 [0.28, 0.86] | P = 0.01 |
| Asia                      | 19(18%)       | 8(8%)         | 2.46 [1.02, 5.90] | P = 0.04 |
| Australia                 | 10(9%)        | 4(4%)         | 2.45 [0.74, 8.08] | P = 0.14 |
| Center                    |               |               |            |         |
| Single-center             | 31(29%)       | 51(52%)       | 0.38 [0.22, 0.68] | P = 0.001 |
| Multi-center              | 76(71%)       | 48(48%)       | 2.60 [1.47, 4.63] | P = 0.001 |
| Funding source            |               |               |            |         |
| Industry                  | 43(40%)       | 25(25%)       | 1.99 [1.10, 3.61] | P = 0.02 |
| Public                    | 40(38%)       | 32(32%)       | 1.25 [0.70, 2.22] | P = 0.45 |
| Public and industry       | 13(12%)       | 8(8%)         | 1.57 [0.62, 3.97] | P = 0.34 |
| Not specified             | 5(5%)         | 33(33%)       | 0.10 [0.04, 0.26] | P < 0.001 |
| None                      | 6(5%)         | 1(1%)         | 5.82 [0.69, 49.24] | P = 0.11 |
| Ethics committee approval | 105(98%)      | 86(87%)       | 7.94 [1.74, 36.13] | P = 0.007 |
| Informed consent from patients | 100(93%) | 81(82%) | 3.17 [1.26, 7.97] | P = 0.01 |

Wang et al. BMC Medical Research Methodology 2011, 11:110
http://www.biomedcentral.com/1471-2288/11/110
withdrawals were adequately described in 70% of RCTs. However, this item was reported only in 30% of RCTs published in the five major gastroenterology and hepatology journals in 1998 and 49% of RCTs published in 2008.

As for the effects of funds upon methodological reporting quality, though there were different opinions [20,21], industry-sponsored trials were reported to have better reporting of methodology than non-industry sponsored trials [15,22,23]. For example, both Brown A [22] and Thomas O’s [23] study have found that trials with industry funding had a higher methodology score than those with public funding. Bai Y’s study [15] indicated that those industry-sponsored trials had better reporting of double blinding than public sponsored trials. We also found that industry-sponsored trials were significantly more likely to report the item of sequence allocation concealment and blinding. Compared with single-center trials, more participants were recruited by the multi-center collaboration, which resulted in an

| Items                          | 2008(n = 107) | 1998(n = 99) | 2008 VS 1998 | P value |
|-------------------------------|--------------|--------------|--------------|---------|
| **Sequence generation**       |              |              |              |         |
| adequate reporting            | 23(22%)      | 10(10%)      | 2.44[1.09, 5.42] | < 0.05  |
| partial reporting             | 58(54%)      | 25(25%)      | < 0.05       |         |
| no reporting                  | 26(24%)      | 64(75%)      | < 0.05       |         |
| *adequate + partial reporting | 81(76%)      | 35(35%)      | 5.70[3.11, 10.42] | < 0.05  |
| **Allocation concealment**    |              |              |              |         |
| adequate reporting            | 66(6%)       | 3(3%)        | 1.90[0.46, 7.82] | 0.89    |
| partial reporting             | 56(52%)      | 22(22%)      | < 0.05       |         |
| no reporting                  | 45(42%)      | 74(75%)      | < 0.05       |         |
| *adequate + partial reporting | 62(58%)      | 25(25%)      | 4.08 [2.25, 7.39] | < 0.05  |
| **Blinding**                  |              |              |              |         |
| adequate reporting            | 24(22%)      | 22(22%)      | 1.01[0.52, 1.95] | 0.97    |
| partial reporting             | 38(36%)      | 30(30%)      | < 0.05       |         |
| no reporting                  | 45(42%)      | 47(47%)      | 0.43         |         |
| *adequate + partial reporting | 62(58%)      | 52(53%)      | 1.25 [0.72, 2.16] | 0.43    |
| **Sample size calculation**   |              |              |              |         |
| adequate reporting            | 28(26%)      | 13(13%)      | 2.34[1.14, 4.84] | < 0.05  |
| partial reporting             | 55(52%)      | 34(34%)      | < 0.05       |         |
| no reporting                  | 24(22%)      | 52(53%)      | < 0.05       |         |
| *adequate + partial reporting | 83(78%)      | 47(47%)      | 3.83 [2.10, 6.98] | < 0.05  |
| **Incomplete outcome data addressed** | | | | |
| adequate reporting            | 20(19%)      | 12(12%)      | 1.67[0.77, 3.62] | 0.2     |
| partial reporting             | 32(30%)      | 22(22%)      | 0.21         |         |
| no reporting                  | 55(51%)      | 65(66%)      | < 0.05       |         |
| *adequate + partial reporting | 52(49%)      | 34(34%)      | 1.81[1.03, 3.17] | < 0.05  |
| **Intention-to-treat analysis** | | | | |
| adequate reporting            | 49(46%)      | 30(30%)      | 1.94[1.10, 3.45] | < 0.05  |
| partial reporting             | 25(23%)      | 12(12%)      | < 0.05       |         |
| no reporting                  | 33(31%)      | 57(58%)      | < 0.05       |         |
| *adequate + partial reporting | 74(69%)      | 42(42%)      | 3.04 [1.72, 5.39] | < 0.05  |
| **Free of selective reporting** | | | | |
| adequate reporting            | 34(32%)      | 20(20%)      | 1.84[0.97, 3.48] | 0.06    |
| partial reporting             | 23(21%)      | 23(23%)      | 0.76         |         |
| no reporting                  | 50(47%)      | 56(57%)      | 0.16         |         |
| *adequate + partial reporting | 57(53%)      | 43(43%)      | 1.48[0.86, 2.57] | 0.16    |
increase in test performance [24]. We examined the difference of methodological reporting quality between single-center and multi-center trials and found only blinding and "intention to treatment" analysis were better in multi-center trials though it was believed that prospective studies, undertaken in collaboration (either jointly or in parallel), could lead to the development of treatments that are truly beneficial for patients with these diseases [25].

In addition, we also compared this study with previous studies [15-18] focusing on reporting methodological quality of RCTs published in one or more gastroenterology and hepatology journals, and found an improvement of almost all methodological items after the revised version of CONSORT in 2001 (Shown in Table 4). Compared with those studies [15-18], we have done a more comprehensive evaluation of the methodological reporting, while some of the methodological items were seldom assessed in previous studies, especially the items related to incomplete outcome, ITT analysis and free of selective reporting, which are also important for readers to assess the internal validity of the RCTs.

In this study, we used a standardized and rigorous evaluation instrument to assess the reporting of key methodological items systematically, and the abstraction processes were independently performed by two qualified reviewers. However, there were still limitations in this study. Firstly, we only included five major journals and only assessed RCTs for two years due to time and resource constraints, so the results could not represent the methodological reporting quality of the entire range of gastroenterology and hepatology journals. Secondly, we did not compare the methodological reporting quality of these five journals before and after adopting the

| Table 3 Methodological reporting in 2008 according to center and funding source |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                 | Sequence generation | Allocation concealment | Blinding | Sample size calculation | Incomplete outcome | Intention-to-treat analysis | Free of selective reporting |
| Center                          | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| Single-center                   | 20(64%) | 14(45%) | 13(42%) | 21(68%) | 17(55%) | 17(55%) | 21(68%) |
| (n = 31)                        |       |       |       |       |       |       |       |
| Multi-center                    | 61(80%) | 48(63%) | 40(64%) | 62(82%) | 35(46%) | 57(75%) | 36(47%) |
| (n = 76)                        |       |       |       |       |       |       |       |
| P value                         | 0.08 | 0.09 | 0.03 | 0.12 | 0.41 | 0.04 | 0.06 |
| Funding source                  |       |       |       |       |       |       |       |
| Industry                        | 37(86%) | 31(72%) | 30(70%) | 34(80%) | 18(42%) | 28(65%) | 21(49%) |
| (n = 43)                        |       |       |       |       |       |       |       |
| Public                          | 28(70%) | 20(50%) | 19(48%) | 30(75%) | 23(58%) | 28(72%) | 25(63%) |
| (n = 40)                        |       |       |       |       |       |       |       |
| P value                         | 0.07 | 0.04 | 0.04 | 0.66 | 0.16 | 0.64 | 0.21 |

*The current study included the five journals: American Journal of Gastroenterology, Gut, the Journal of Hepatology, Gastroenterology, Hepatology.

The study of Bai included six journals: Gastroenterology, Hepatology, Gut, Journal of Hepatology, American Journal of Gastroenterology, Clinical Gastroenterology and Hepatology.

| Table 4 Methodological reporting in major hepato-gastroenterology journals in different years |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Study period                    | Gluud [17] | Kjaergard [16] | Current study | Kjaergard [18] | Bai [15] | Current study |
| Included journals               | the Journal of Hepatology | Hepatology | 5* | Gastroenterology | 6* | 5* |
| Number of RCTs                  | 166 | 235 | 99 | 383 | 105 | 107 |
| Sequence generation             | 47(28%) | 121(51%) | 35(35%) | 16(42%) | 85(81%) | 81(76%) |
| Allocation concealment          | 22(13%) | 80(34%) | 25(25%) | 149(39%) | 64(61%) | 62(58%) |
| Sample size calculation         | 50(30%) | 80(34%) | 52(33%) | 237(62%) | 54(51%) | 62(58%) |
| Intention-to-treat analysis     | 33(20%) | 61(26%) | 47(47%) | - | 79(75%) | 83(78%) |
| Free of selective reporting     | - | 165(70%) | 34(34%) | - | - | 52(49%) |
CONSORT statement. We did attempt to find out when the CONSORT statement was adopted by each journal, but were unable to do so for three of them.

Conclusions
Our analysis, although not exhaustive, suggests a significant improvement between 1998 and 2008 in the reporting quality of key methodological items in the major gastroenterology and hepatology journals, which is most likely the result of compliance with the CONSORT Statement. However, we can see that there is still ample room for improvement. Now the CONSORT Statement 2010 edition has been published, we call on authors and journal editors, especially those in Asia, to support and implement it in order to enhance the quality of RCT reporting.

Funding
This work was supported by a grant from the Ministry of Public Health, China (No: 200802094) and the National Science Foundation of China (30830055) for Fang JY.

Authors’ contributions
JW and TS designed this study and extracted the data. JW, TS and YL conducted the statistical analyses and created the first draft of the manuscript. All authors participated in editing the manuscript and approved final manuscript for publication.

Competing interests
The authors declare that they have no competing interests.

Received: 25 September 2010 Accepted: 30 July 2011

References
1. Rennie D: CONSORT revised—improving the reporting of randomized trials. JAMA 2001, 285(15):2006-7.
2. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995, 273(5):408-412.
3. Moher D, Jadad A, Klassen A, Cook D, Jadad A, Moher M, Tugwell P, Klassen T: Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998, 352(9128):609-613.
4. Kjaergard LL, Villumsen J, Gluud C: Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001, 135(11):982-989.
5. CONSORT: CONSORT endorsed journals. [http://www.consort-statement.org/about-consort/consort-endorsement/consort-endorsers—journals/]
6. CONSORT: CONSORT endorser: Editorialgroups. [http://www.consort-statement.org/about-consort/consort-endorsement/consort-endorsers—organizations/]
7. Moher D, Jones A, Lepage L: Use of the CONSORT statement and quality of reports of randomized trials: a comparative before and after evaluation. JAMA 2001, 285(15):1992-1995.
8. Egger M, Juni P, Bartlett C: Value of flow diagrams in reports of Randomized controlled trials. JAMA 2001, 285(15):1996-1999.
9. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. 2009 [http://www.Cochrane-handbook.org/]
10. Moher D, Hopewell S, Schulz K, Montori V, Gøtzsche P, Devereaux P, Elbourne D, Egger M, Altman D: CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340:c869.

11. Landsis J, Koch G: An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977, 33(2):363-374.
12. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995, 273(5):408-412.
13. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I: Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. JAMA 2006, 185(5):263-267.
14. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA: Empirical evidence of bias in treatment effect estimates in controlled trials with different intervention and outcomes: a meta-epidemiological study. BMJ 2008, 336(7441):561-565.
15. Bai Y, Gao J, Zou DW, Li ZS: Methodological Reporting of Randomized Clinical Trials in Major Gastroenterology and Hepatology Journals in 2006. Hepatology 2009, 49:2109-2102.
16. Kjaergard LL, Nikolova D, Gluud C: Randomized clinical trials in HEPATOLOGY: predictors of quality. Hepatology 1999, 30:134-138.
17. Gluud C, Nikolova D: Quality assessment of reports on clinical trials in the Journal of Hepatology. J Hepatol 1998, 29:321-327.
18. Kjaergard LL, Frederiksen SL, Gluud C: Validity of randomized clinical trials in gastroenterology from 1964-2000. Gastroenterology 2002, 122:1157-1160.
19. Gibson CA, Kirk EP, LeCheminant JD, Bailey BW Jr, Huang G, Donnelly JE: Reporting quality of randomized trials in the diet and exercise literature for weight loss. BMJ Med Res Methods 2005, 5(119).
20. Jørgensen AW, Maric KL, Tendal B, Faurchou A, Gøtzsche PC: Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions. BMJ Med Res Methods 2008, 8(60).
21. Clifford TJ, Barrowman NJ, Moher D: Funding source, trial outcome and reporting quality: are they related? Results of a pilot study. BMC Health Serv Res 2002, 2(1):18.
22. Brown A, Kraft D, Schmitz S, Sharpless V, Martin C, Shah R, Shaheen N: Association of industry sponsorship to published outcomes in gastrointestinal clinical research. Clin Gastroenterol Hepatol 2006, 4(12):1445-1451.
23. Thomas O, Thabane L, Douketis J, Chu R, Westfall AO, Allison DB: Industry funding and the reporting quality of large long-term weight loss trials. Int J Obes (Lond) 2008, 32(10):1531-6.
24. Yusuf S, Collins R, Peto R: Why do we need some large, simple randomized trials? Stat Med 1984, 3:403-422.
25. Furuse J, Okusaka T, Bridgewater J, Taketsuna M, Wasan H, Koshiji M, Valle J: Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Crit Rev Oncol/Hematol 2010.